PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 14, 2026European Respiratory Journal0 citations

Pro-adrenomedullin, pro-atrial natriuretic peptide and procalcitonin levels at admission in patients with community-acquired pneumonia and its correlation with risk scores

View Full Paper
ALAlicia Mayoral LacomaABAlbert BasPTPere Tudela

Key Result

Higher levels of MR-proANP and MR-proADM at admission correlate with increased pneumonia severity assessed by CURB65 and SCAP scores in patients with community-acquired pneumonia.

Key Points

  • The study aims to evaluate the levels of specific biomarkers in community-acquired pneumonia and their relationship to severity scores and outcomes.
  • 85 patients diagnosed with community-acquired pneumonia were analyzed.
  • Plasma samples collected at admission to assess biomarkers MR-proADM, MR-proANP, and PCT.
  • Patients stratified by PSI, CURB65, and SCAP severity scores.
  • Data concerning clinical, epidemiological, and radiological aspects were recorded.
  • MR-proANP and MR-proADM showed significant differences across the PSI score (p=0.001).
  • Both biomarkers increased significantly with higher CURB65 scores (p=0.001).
  • Patients meeting SCAP criteria had higher levels of MR-proANP (p=0.002) and MR-proADM (p=0.001).
  • Higher levels of MR-proADM and MR-proANP were associated with increased ICU admissions (p=0.001).
  • Although biomarker levels were higher in non-survivors, no statistical differences were found.

Structured PICO

Do admission levels of MR-proADM, MR-proANP and PCT correlate with severity risk scores and prognosis in patients with community-acquired pneumonia?

P
Population
Patients with diagnosis of community-acquired pneumonia (CAP)
I
Intervention
Measurement of MR-proADM, MR-proANP and PCT levels at admission
O
Outcome
Correlation of admission biomarker levels with severity risk scores (PSI, CURB65 and SCAP) and prognosis (ICU admission or death)surrogate

Admission levels of MR-proANP and MR-proADM correlate with pneumonia severity scores and may help identify patients with a poorer prognosis.

Abstract

Objectives: To assess levels of MR-proADM, MR-proANP and PCT in patients with community acquired pneumonia (CAP) and to correlate admission levels with the following severity risk scores: PSI, CURB65 and severe CAP (SCAP) and prognosis. Methods: Study population was 85 patients with diagnosis of pneumonia. Epidemiological, clinical, microbiological, analytical and radiological data were recorded. Plasma samples were collected at admission. Patients were stratified according to the PSI, CURB65 and SCAP. Complications were defined as need of ICU admission or death. Results: MR-proANP and MR-proADM showed significant differences across PSI score (p=0.001 and p=0.001) whereas no statistical differences were found for PCT (p=0.152). Regarding CURB65, MR-proANP and MR-proADM levels increased according to CURB65 score points (p=0.001 and p=0.001), but not PCT (p=0.071). Higher levels of MR-proANP (p=0.002), proADM (p=0.001) and PCT (p=0.069) were found in patients with SCAP criteria. MR-proADM (p=0.001) and MR-proANP (p=0.015) showed statistical differences when grouping SCAP in five risk groups. Levels of PCT (p=0.053) and MR-proADM (p=0.001) were significantly higher in patients admitted to ICU. Levels of all biomarkers were higher in non-survivors in comparison to survivors, although no statistical differences were found. Conclusions: Admission MR-proANP and MR-proADM levels correlate with pneumonia severity assessed by PSI, CURB65 and SCAP. PCT levels correlate with new severity SCAP index. Higher biomarkers levels can be useful for identifying patients with a poorer prognosis.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Lacoma et al. (2011) studied this question. Higher levels of MR-proANP and MR-proADM at admission correlate with increased pneumonia severity assessed by CURB65 and SCAP scores in patients with community-acquired pneumonia.

synapsesocial.com/papers/69b4fb9db39f7826a300bfb6https://doi.org/10.1183/13993003/erj.38.suppl_55.p1468
Ask AI
Helpful
Bookmark
Share
View Full Paper